ClinicalTrials.gg
CompletedNCT02196701CLEARUpdated Mar 19, 2018Results posted

Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study

A Phase 3 interventional study of Adalimumab and Methotrexate in Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-19.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
38th of 48
46 · median 148
Started
2014
with 1 other
Phase 3
26 of 48
1 open now
Registered
30th of 48
by date
Lead sponsor
3 of 48
AbbVie

Among the 48 studies testing adalimumab in Psoriasis, this one is the 38th largest by enrollment, is one of 2 that started in 2014, is one of 26 in phase 3, and was the 30th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • methotrexate
  • adalimumab
  • biologic
  • psoriasis
  • Tumor necrosis factor (TNF)-α inhibitor
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have been on ADA monotherapy (40 mg eow or greater) for at least 16 weeks but who in the opinion of the Investigator have shown a sub-optimal response to treatment and have a Physician's Global Assessment (PGA) of ≥ 3 and a Psoriasis Area Severity Index (PASI) of ≥ 5; or Subjects who after an initial positive response to ADA monotherapy (40 mg eow or greater) have failed to maintain an optimal level of response, based on the opinion of the Investigator, and have a PGA of ≥ 3 and a PASI of ≥ 5;
  2. Subjects who are receiving 40 mg ADA once weekly must be on ADA 40 mg eow for 8 weeks prior to screening;
  3. Subjects with at least a 6 month history of chronic plaque psoriasis;
  4. Subjects greater than or equal to 18 years of age;
  5. If female, subject is either not of , defined as for at least 1 year or surgically sterile or is of childbearing potential and is practicing ;
  6. The results of the serum pregnancy test performed during the Screening Period and urine pregnancy test performed at the Baseline Visit must be negative;
  7. Subject is judged to be in good general health as determined by the Principal Investigator;
  8. Subjects must be evaluated for latent tuberculosis (TB) infection;
  9. Subjects must be able and willing to provide written and comply with the requirements of the study protocol;
  10. Subjects must be willing and able to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.

Exclusion criteria

Exclusion Criteria:

  1. Subject has any to MTX or ADA;
  2. Subject has a previous failed response or poor tolerance to ADA;
  3. Subject has a poorly controlled medical condition which, in the opinion of the Investigator, would put the subject at risk by participation in the study;
  4. Subject has a history of hematologic, renal or liver disease;
  5. Subject has a history of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease and/or diagnosis of central demyelinating disease;
  6. Subject has evidence of dysplasia or history of (including lymphoma and leukemia) other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix;
  7. Subject has a history of listeriosis, histoplasmosis, untreated TB, persistent chronic infections, or recent active infections requiring hospitalization or treatment with intravenous (iv) anti-infectives within 30 days or oral anti-infectives within 14 days prior to the Baseline visit;
  8. Subject is known to have immune deficiency, history of (HIV) or is ;
  9. Subject currently uses or plans to use anti-retroviral therapy at any time during the study;
  10. Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study or for 150 days after the last dose of study medication;
  11. Subject has a history of clinically significant drug or alcohol usage in the last year or cannot maintain an alcohol intake of 30 g a day or less throughout the study (one standard drink is defined as 180 mL/6 oz (approx. 10 g) of wine, 360 mL/12 oz (approx. 15 g) of regular beer, or 45 mL/1.5 oz (approx. 10 g) of spirits;
  12. Screening clinical laboratory analyses show any of the following abnormal laboratory results:

    • (AST) or alanine transaminase (ALT) > 2x the (ULN);
    • Serum total > 1.5 mg/dL (> 26 micromol/L), except for subjects with Gilbert's Syndrome;
    • Creatinine > 1.5 mg/dL (133 micromol/L) in subjects ≤ 65 years old and > upper limit of normal range in subjects > 65;
    • Positive or C serology indicative of previous or current infection.
  13. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study;
  14. The following treatments are prohibited for all subjects during the study:

    • Phototherapy (ultraviolet A with psoralen [PUVA] within 4 weeks of the Baseline Visit and/or ultraviolet B (UVB) within 2 weeks of the Baseline Visit);
    • Other biologic therapies (including any other anti-tumor necrosis factor [TNF]) within 4 weeks of the Baseline Visit;
    • Any agents of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to the Baseline visit ;
    • Any other systemic drug therapies for psoriasis within 4 weeks of the Baseline Visit;
    • Oral or injectable , new prescription topical therapies, or changes in the concentration of current prescription topical therapies (including corticosteroids) that are being used, within 2 weeks of the Baseline Visit. Subjects may continue using previously prescribed topical therapies (including corticosteroids) during the study.
  15. Prior exposure to biologics that have a potential or known association with progressive multifocal leukoencephalopathy (PML), i.e., natalizumab (Tysabri®) or rituximab (Rituxan®);
  16. Subjects with any active viral infection that based on the investigator's clinical assessment makes the subject an unsuitable candidate for the study;
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Adalimumab Plus Methotrexate

    Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.

    Drug: Adalimumab · Drug: Methotrexate

Interventions

  • Administered by subcutaneous injection every other week.

    Also known as: Humira

  • Methotrexate was provided as 2.5 mg tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment

    Study investigators were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

    Time frame: Week 16

  2. Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment

    Participants were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving a Satisfactory Response Based on Investigator Assessment Over Time

    Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

    Time frame: Baseline, week 8 and week 24

  2. Percentage of Participants Achieving a Satisfactory Response Based on Patient Self-assessment Over Time

    Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

    Time frame: Baseline, week 8 and week 24

  3. Number of Participants Achieving Each Satisfactory Category Based on Investigator Assessment Over Time

    Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied

    Time frame: Baseline, weeks 8, 16, and 24

  4. Number of Participants Achieving Each Satisfactory Category Based on Patient Self-assessment Over Time

    Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied

    Time frame: Baseline, weeks 8, 16, and 24

  5. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 50 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is defined as at least a 50% reduction (improvement) from baseline in PASI score.

    Time frame: Baseline and Weeks 8, 16, and 24

  6. Percentage of Participants Who Achieved a PASI 75 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from baseline in PASI score.

    Time frame: Baseline and Weeks 8, 16, and 24

  7. Percentage of Participants Who Achieved a PASI 90 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is defined as at least a 90% reduction (improvement) from baseline in PASI score.

    Time frame: Baseline and Weeks 8, 16, and 24

  8. Percentage of Participants Who Achieved a PASI 100 Response Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is defined as a 100% reduction (improvement) from baseline in PASI score.

    Time frame: Baseline and Weeks 8, 16, and 24

  9. Change From Baseline in PASI Score Over Time

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

    Time frame: Baseline and weeks 8, 16, and 24

  10. Percent Change From Baseline in PASI Score

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

    Time frame: Baseline and weeks 8, 16, and 24

  11. Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of Cleared or Minimal Over Time

    The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

    Time frame: Weeks 8, 16, and 24

  12. Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

    The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.

    Time frame: Baseline and weeks 8, 16, and 24

  13. Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

    The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.

    Time frame: Baseline and weeks 8, 16, and 24

  14. Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.

    Time frame: Baseline, weeks 8, 16, and 24

  15. Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.

    Time frame: Baseline, weeks 8, 16, and 24

  16. Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Over Time

    The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.

    Time frame: Baseline and Weeks 8, 16, and 24

  17. Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24

    Time frame: Baseline and week 24

07

Results

Posted Mar 19, 2018

Participant flow

This single-arm, open-label longitudinal study was conducted at 12 sites in Canada from 5 August 2014 to 17 March 2017. The study entailed a screening period up to 35 days, a 24-week treatment period, and a 70-day safety follow-up period. Participants continued to receive adalimumab (ADA) and had oral methotrexate (MTX) added to their treatment.

Participant flow — Overall Study
MilestoneAdalimumab + Methotrexate
Started46
Completed43
Not completed3
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Non-adherence to protocol1

Outcome measures

PrimaryPercentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment

Study investigators were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment33.3 (0.0 to 71.1)52.5 (37.0 to 68.0)50.0 (35.6 to 64.4)
PrimaryPercentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment

Participants were asked to complete the following questionnaire at week 16: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment16.7 (0.0 to 46.5)52.5 (37.0 to 68.0)47.8 (33.4 to 62.3)
SecondaryPercentage of Participants Achieving a Satisfactory Response Based on Investigator Assessment Over Time

Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

Time frame:
Baseline, week 8 and week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Satisfactory Response Based on Investigator Assessment Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Baseline0 (0.0 to 0.0)0 (0.0 to 0.0)0 (0.0 to 0.0)
Week 850.0 (10.0 to 90.0)42.5 (27.2 to 57.8)43.5 (29.2 to 57.8)
Week 2433.3 (0.0 to 71.1)60.0 (44.8 to 75.2)56.5 (42.2 to 70.8)
SecondaryPercentage of Participants Achieving a Satisfactory Response Based on Patient Self-assessment Over Time

Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied Satisfaction with therapy was defined by the combination of highly or completely satisfied responses.

Time frame:
Baseline, week 8 and week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Satisfactory Response Based on Patient Self-assessment Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Baseline0 (0.0 to 0.0)17.5 (5.7 to 29.3)15.2 (4.8 to 25.6)
Week 816.7 (0.0 to 46.5)52.5 (37.0 to 68.0)47.8 (33.4 to 62.3)
Week 2416.7 (0.0 to 46.5)60.0 (44.8 to 75.2)54.3 (40.0 to 68.7)
SecondaryNumber of Participants Achieving Each Satisfactory Category Based on Investigator Assessment Over Time

Study investigators were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with the psoriasis control provided by the subject's current treatment regimen? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied

Time frame:
Baseline, weeks 8, 16, and 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Each Satisfactory Category Based on Investigator Assessment Over Time
ParticipantsAdalimumab + Methotrexate
Baseline — Completely satisfied0
Baseline — Highly satisfied0
Baseline — Slightly satisfied8
Baseline — Moderately dissatisfied31
Baseline — Completely dissatisfied7
Baseline — Missing0
Week 8 — Completely satisfied6
Week 8 — Highly satisfied14
Week 8 — Slightly satisfied15
Week 8 — Moderately dissatisfied9
Week 8 — Completely dissatisfied1
Week 8 — Missing1
Week 16 — Completely satisfied8
Week 16 — Highly satisfied15
Week 16 — Slightly satisfied10
Week 16 — Moderately dissatisfied8
Week 16 — Completely dissatisfied3
Week 16 — Missing2
Week 24 — Completely satisfied11
Week 24 — Highly satisfied15
Week 24 — Slightly satisfied7
Week 24 — Moderately dissatisfied6
Week 24 — Completely dissatisfied4
Week 24 — Missing3
SecondaryNumber of Participants Achieving Each Satisfactory Category Based on Patient Self-assessment Over Time

Participants were asked to complete the following questionnaire at each scheduled visit: Overall, at this point in time, how satisfied are you with your current treatment for psoriasis? The response choices provided were: * Completely dissatisfied * Moderately dissatisfied * Slightly satisfied * Highly satisfied * Completely satisfied

Time frame:
Baseline, weeks 8, 16, and 24
Reported as:
Count of participants · Participants
Number of Participants Achieving Each Satisfactory Category Based on Patient Self-assessment Over Time
ParticipantsAdalimumab + Methotrexate
Baseline — Completely satisfied5
Baseline — Highly satisfied2
Baseline — Slightly satisfied15
Baseline — Moderately dissatisfied17
Baseline — Completely dissatisfied7
Baseline — Missing0
Week 8 — Completely satisfied10
Week 8 — Highly satisfied12
Week 8 — Slightly satisfied14
Week 8 — Moderately dissatisfied7
Week 8 — Completely dissatisfied2
Week 8 — Missing1
Week 16 — Completely satisfied7
Week 16 — Highly satisfied15
Week 16 — Slightly satisfied13
Week 16 — Moderately dissatisfied6
Week 16 — Completely dissatisfied3
Week 16 — Missing2
Week 24 — Completely satisfied10
Week 24 — Highly satisfied15
Week 24 — Slightly satisfied7
Week 24 — Moderately dissatisfied6
Week 24 — Completely dissatisfied5
Week 24 — Missing3
SecondaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 50 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 50 response is defined as at least a 50% reduction (improvement) from baseline in PASI score.

Time frame:
Baseline and Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 50 Response Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 850.0 (10.0 to 90.0)42.5 (27.2 to 57.8)43.5 (29.2 to 57.8)
Week 1650.0 (10.0 to 90.0)62.5 (47.5 to 77.5)60.9 (46.8 to 75.0)
Week 2466.7 (28.9 to 100.0)65.0 (50.2 to 79.8)65.2 (51.5 to 79.0)
SecondaryPercentage of Participants Who Achieved a PASI 75 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 75 response is defined as at least a 75% reduction (improvement) from baseline in PASI score.

Time frame:
Baseline and Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 75 Response Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 833.3 (0.0 to 71.1)27.5 (13.7 to 41.3)28.3 (15.2 to 41.3)
Week 1616.7 (0.0 to 46.5)42.5 (27.2 to 57.8)39.1 (25.0 to 53.2)
Week 2416.7 (0.0 to 46.5)42.5 (27.2 to 57.8)39.1 (25.0 to 53.2)
SecondaryPercentage of Participants Who Achieved a PASI 90 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 90 response is defined as at least a 90% reduction (improvement) from baseline in PASI score.

Time frame:
Baseline and Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 90 Response Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 816.7 (0.0 to 46.5)12.5 (2.3 to 22.7)13.0 (3.3 to 22.8)
Week 1616.7 (0.0 to 46.5)15.0 (3.9 to 26.1)15.2 (4.8 to 25.6)
Week 2416.7 (0.0 to 46.5)30.0 (15.8 to 44.2)28.3 (15.2 to 41.3)
SecondaryPercentage of Participants Who Achieved a PASI 100 Response Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI 100 response is defined as a 100% reduction (improvement) from baseline in PASI score.

Time frame:
Baseline and Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a PASI 100 Response Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 816.7 (0.0 to 46.5)12.5 (2.3 to 22.7)13.0 (3.3 to 22.8)
Week 1616.7 (0.0 to 46.5)10.0 (0.7 to 19.3)10.9 (1.9 to 19.9)
Week 2416.7 (0.0 to 46.5)27.5 (13.7 to 41.3)26.1 (13.4 to 38.8)
SecondaryChange From Baseline in PASI Score Over Time

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

Time frame:
Baseline and weeks 8, 16, and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI Score Over Time
units on a scalePrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-4.6 ± 2.07-4.6 ± 0.65-4.6 ± 0.61
Week 16-4.5 ± 1.31-6.2 ± 0.59-5.9 ± 0.53
Week 24-3.1 ± 3.17-6.3 ± 0.68-5.9 ± 0.74
SecondaryPercent Change From Baseline in PASI Score

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis).

Time frame:
Baseline and weeks 8, 16, and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in PASI Score
percent changePrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-51.6 ± 16.23-43.7 ± 6.11-44.8 ± 5.64
Week 16-45.6 ± 15.15-59.2 ± 5.06-57.3 ± 4.74
Week 24-17.4 ± 45.65-63.7 ± 5.78-58.1 ± 8.01
SecondaryPercentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of Cleared or Minimal Over Time

The PGA is a 6-point scale used to measure the severity of disease at the time of the evaluation. The degree of overall lesion severity was evaluated using the following categories: * 0 (Cleared): No evidence of scaling, erythema, or plaque elevation; * 1 (Minimal): Occasional fine scale over \<5% of lesions, faint erythema, minimal plaque elevation; * 2 (Mild): Fine scale dominates, light red coloration, mild plaque elevation; * 3 (Moderate): Course scale dominates, moderate red coloration, moderate plaque elevation; * 4 (Marked): Thick non-tenacious scale dominates, bright red coloration, marked plaque elevation; * 5 (Severe): Very thick tenacious scale predominates, dusky to deep red coloration, severe plaque elevation. The percentage of participants achieving a score of clear (0) or minimal (1) is reported.

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of Cleared or Minimal Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 816.7 (0.0 to 46.5)27.5 (13.7 to 41.3)26.1 (13.4 to 38.8)
Week 1616.7 (0.0 to 46.5)35.0 (20.2 to 49.8)32.6 (19.1 to 46.2)
Week 2416.7 (0.0 to 46.5)47.5 (32.0 to 63.0)43.5 (29.2 to 57.8)
SecondaryChange From Baseline in Body Surface Area (BSA) Affected by Psoriasis

The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.

Time frame:
Baseline and weeks 8, 16, and 24
Reported as:
Least squares mean · percentage of body surface area
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
percentage of body surface areaPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-3.5 ± 2.95-4.5 ± 1.06-4.4 ± 0.98
Week 16-4.5 ± 2.40-6.4 ± 1.08-6.2 ± 0.99
Week 24-4.1 ± 1.57-6.3 ± 0.89-6.0 ± 0.79
SecondaryPercent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

The total body surface area affected by psoriasis (expressed as a percentage) was measured by the investigator using the palm method, where the participant's hand represents 1% of body surface area. A decrease in BSA affected by psoriasis indicates improvement.

Time frame:
Baseline and weeks 8, 16, and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
percent changePrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-33.9 ± 23.10-34.1 ± 7.48-33.4 ± 7.17
Week 16-34.1 ± 22.25-54.2 ± 5.89-51.4 ± 5.89
Week 24-32.7 ± 22.25-61.7 ± 6.33-57.8 ± 6.21
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.

Time frame:
Baseline, weeks 8, 16, and 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
units on a scalePrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-5.0 ± 1.40-4.8 ± 0.71-4.8 ± 0.64
Week 16-3.8 ± 2.54-5.9 ± 0.78-5.6 ± 0.76
Week 24-1.7 ± 4.29-6.3 ± 0.69-5.4 ± 0.88
SecondaryPercent Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all. A negative change from Baseline indicates improvement.

Time frame:
Baseline, weeks 8, 16, and 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time
percent changePrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 8-43.0 ± 21.50-38.6 ± 7.01-39.2 ± 6.48
Week 16-22.9 ± 40.40-38.9 ± 12.79-36.7 ± 11.85
Week 2414.4 ± 71.98-55.0 ± 6.90-44.5 ± 11.11
SecondaryPercentage of Participants Who Achieved a DLQI Score of 0 or 1 Over Time

The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); the range of the total score is 0 to 30. A score of 21 to 30 means an extremely large effect on the participant's life whereas 0-1 means that the disease has no effect at all.

Time frame:
Baseline and Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Over Time
percentage of participantsPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Week 816.7 (0.0 to 46.5)20.0 (7.6 to 32.4)19.6 (8.1 to 31.0)
Week 1616.7 (0.0 to 46.5)40.0 (24.8 to 55.2)37.0 (23.0 to 50.9)
Week 2416.7 (0.0 to 46.5)40.0 (24.8 to 55.2)37.0 (23.0 to 50.9)
SecondaryChange From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24
Time frame:
Baseline and week 24
Reported as:
Least squares mean · mg/L
Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24
mg/LPrimary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXAdalimumab + Methotrexate
Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24-2.6 ± 0.470.1 ± 1.52-0.3 ± 1.32

Adverse events

Collected over From the date of either the first dose of study adalimumab or the first dose of methotrexate up to 70 days after the last adalimumab injection during the study. The median duration of exposure to adalimumab was 168 days (range: 14 - 171 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab + Methotrexate0/46 (0%)1/46 (2.2%)27/46 (58.7%)
Most frequent serious events
Most frequent serious events
EventAdalimumab + Methotrexate
Cardiac arrestCardiac disorders1/46
Generalised tonic-clonic seizureNervous system disorders1/46
Loss of consciousnessNervous system disorders1/46
HypercapniaRespiratory, thoracic and mediastinal disorders1/46
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAdalimumab + Methotrexate
NasopharyngitisInfections and infestations7/46
Upper respiratory tract infectionInfections and infestations5/46
NauseaGastrointestinal disorders3/46
BronchitisInfections and infestations3/46
FatigueGeneral disorders2/46
GastroenteritisInfections and infestations2/46
PneumoniaInfections and infestations2/46
SinusitisInfections and infestations2/46
Tooth abscessInfections and infestations2/46
Urinary tract infectionInfections and infestations2/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
Mean41.0 ± 13.8447.3 ± 11.9146.5 ± 12.20
Age, Customized
Age, Customized(Participants)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
< 40 years21315
40 - 64 years42226
≥ 65 years055
Sex: Female, Male
Sex: Female, Male(Participants)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
Female2911
Male43135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
Hispanic or Latino011
Not Hispanic or Latino63945
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
White43135
Black011
Asian2810
Duration of Psoriasis
Duration of Psoriasis(years)Primary Sub-optimal Responders - ADA + MTXSecondary Sub-optimal Responders - ADA + MTXTotal
Mean20.623 ± 10.481921.760 ± 9.740321.612 ± 9.7253
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Mar 2017, 31 months.

Results were first posted in Mar 2018, 1 year after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 22, 2014
StartActual
Aug 5, 2014
Primary completionActual
Mar 17, 2017
CompletionActual
Mar 17, 2017
Results first posted
Mar 19, 2018
Last update
Mar 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02196701
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 22, 2014
Start date
Aug 5, 2014
Primary completion
Mar 17, 2017
Completion
Mar 17, 2017
Results posted
Mar 19, 2018
Last update
Mar 19, 2018

Study contacts

Marc-André Raymond, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Methotrexate

Start the discussion